Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive trial results and analyst confidence drove Pharvaris's stock to a 52-week high, boosting its market cap to about $2.64 billion. The company plans to seek marketing approval in the first half of 2027 based on these strong results. This development highlights Pharvaris's potential to offer easier treatment options for HAE patients.
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Casey's General Stores reported strong Q1 2026 results, surpassing analyst expectations with an EPS of $7.37 versus $6.78 estimated and revenue of $5.68 billion beating the $5.56 billion forecast. Net income rose 27.1% year-over-year to $273.7 millio...
Academy Sports and Outdoors will announce its Q2 2026 earnings on September 9, with revenue expected to rise 3.8% year-over-year to about $1.66 billion. Analysts forecast earnings per share between $2.07 and $2.12, up from $1.94 last year, indicating...
Inhibrx Biosciences CEO Lappe Mark purchased 5,895 shares at $99.29 each following positive Phase 2 trial results for their cancer drug INBRX-106 combined with Keytruda. The trial showed a 48.3% tumor response rate, nearly double that of Keytruda alo...
Chewy will report its Q2 2026 earnings on September 9, with analysts expecting earnings per share (EPS) of $0.36, a 9.1% increase year-over-year, and revenue of $3.32 billion, up 6.8%. Growth is driven by its Autoship subscription program and expansi...
